Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,028

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

Open access
Hart, Robert G., Sharma, Mukul, Mundl, Hardi, Kasner, Scott E., Bangdiwala, Shrikant I., Berkowitz, Scott D., Swaminathan, Balakumar, Lavados, Pablo, Wang, Yongjun, Wang, Yilong, Davalos, Antonio, Shamalov, Nikolay, Mikulik, Robert, Cunha, Luis, Lindgren, Arne, Arauz, Antonio, Lang, Wilfried, Czlonkowska, Anna, Eckstein, Jens, Gagliardi, Rubens J., Amarenco, Pierre, Ameriso, Sebastian F., Tatlisumak, Turgut, Veltkamp, Roland, Hankey, Graeme J., Toni, Danilo, Bereczki, Daniel, Uchiyama, Shinichiro, Ntaios, George, Yoon, Byung-Woo, Brouns, Raf, Endres, Matthias, Muir, Keith W., Bornstein, Natan, Ozturk, Serefnur, O’Donnell, Martin J., De Vries Basson, Matthys M., Pare, Guillaume, Pater, Calin, Kirsch, Bodo, Sheridan, Patrick, Peters, Gary, Weitz, Jeffrey I., Peacock, W. Frank, Shoamanesh, Ashkan, Benavente, Oscar R., Joyner, Campbell, Themeles, Ellison, Connolly, Stuart J.·2018·New England Journal of Medicine

Abstract

BACKGROUND: Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke than aspirin. METHODS: We compared the efficacy and safety of rivaroxaban (at a daily dose of 15 mg) with aspirin (at a daily dose of 100 mg) for the prevention of recurrent stroke in patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source. The primary efficacy outcome was the first recurrence of ischemic or hemorrhagic stroke or systemic embolism in a time-to-event analysis; the primary safety outcome was the rate of major bleeding. RESULTS: A total of 7213 participants were enrolled at 459 sites; 3609 patients were randomly assigned to receive rivaroxaban and 3604 to receive aspirin. Patients had been followed for a median of 11 months when the trial was terminated early because of a lack of benefit with regard to stroke risk and because of bleeding associated with rivaroxaban. The primary efficacy outcome occurred in 172 patients in the rivaroxaban group (annualized rate, 5.1%) and in 160 in the aspirin group (annualized rate, 4.8%) (hazard ratio, 1.07; 95% confidence interval [CI], 0.87 to 1.33; P=0.52). Recurrent ischemic stroke occurred in 158 patients in the rivaroxaban group (annualized rate, 4.7%) and in 156 in the aspirin group (annualized rate, 4.7%). Major bleeding occurred in 62 patients in the rivaroxaban group (annualized rate, 1.8%) and in 23 in the aspirin group (annualized rate, 0.7%) (hazard ratio, 2.72; 95% CI, 1.68 to 4.39; P<0.001). CONCLUSIONS: Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding. (Funded by Bayer and Janssen Research and Development; NAVIGATE ESUS ClinicalTrials.gov number, NCT02313909 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1802686

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 1,028

Metadata

Authors
Hart, R. G., Sharma, M., Mundl, H., Kasner, S. E., Bangdiwala, S. I., Berkowitz, S. D., Swaminathan, B., Lavados, P., Wang, Y., Wang, Y., Davalos, A., Shamalov, N., Mikulik, R., Cunha, L., Lindgren, A., Arauz, A., Lang, W., Czlonkowska, A., Eckstein, J., Gagliardi, R. J., Amarenco, P., Ameriso, S. F., Tatlisumak, T., Veltkamp, R., Hankey, G. J., Toni, D., Bereczki, D., Uchiyama, S., Ntaios, G., Yoon, B.-W., Brouns, R., Endres, M., Muir, K. W., Bornstein, N., Ozturk, S., O’Donnell, M. J., De Vries Basson, M. M., Pare, G., Pater, C., Kirsch, B., Sheridan, P., Peters, G., Weitz, J. I., Peacock, W. F., Shoamanesh, A., Benavente, O. R., Joyner, C., Themeles, E., & Connolly, S. J.
Venue
New England Journal of Medicine
Published
2018-06-07
Volume
378
Issue
23
Pages
2191-2201
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2803966697
Cited by
1,028
References
6
FWCI
83.35
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. https://app.cochat.ai/papers/10.1056/nejmoa1802686
The paper
Hart, R. G., Sharma, M., Mundl, H., Kasner, S. E., Bangdiwala, S. I., Berkowitz, S. D., Swaminathan, B., Lavados, P., Wang, Y., Wang, Y., Davalos, A., Shamalov, N., Mikulik, R., Cunha, L., Lindgren, A., Arauz, A., Lang, W., Czlonkowska, A., Eckstein, J., . . . Connolly, S. J. (2018). Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1802686

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.